FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311732009> ?p ?o ?g. }

• W4311732009 abstract "Abstract Background Cefiderocol is a novel siderophore cephalosporin and the only beta-lactam that has demonstrated in vitro activity against metallo-beta-lactamase producing organisms. The open-label phase 3 study CREDIBLE-CR unexpectedly found a higher mortality rate in the cefiderocol group compared to best available therapy. Post-approval, real-world clinical data of cefiderocol use are limited. We sought to describe nationwide, real-world outcomes, clinical characteristics, and microbiological characteristics of infections treated with cefiderocol. Cefiderocol use since FDA approval (Nov 2019) Methods The Department of Veterans Affairs (VA) Corporate Data Warehouse was queried to identify any patient prescribed cefiderocol at any of the 171 VA medical centers from date of FDA approval in 11/2019 until 11/2021. Clinical, pharmacy, demographics, and microbiology data were computationally extracted, supplemented by manual review. All patient charts were manually reviewed to determine the indication for cefiderocol and clinical outcomes. Results Twenty-five patients have been prescribed cefiderocol; two received only one dose, and one patient had incomplete records. Prior to 2021 there were four prescription, and since 2021 there have been 21 prescriptions. Of the 22 evaluated patients, their median age was 70 years and 82% were receiving care in the ICU. Infecting organisms (n=25) were Pseudomonas aeruginosa 63%, A. baumannii 18.5%, and Enterobacterales 18.5%. Cefiderocol susceptibility was tested on 17 isolates, of which 15 (88.2%) were susceptible. The two non-susceptible organisms were A. baumannii and P. aeruginosa. The susceptibilities of the 25 strains overall were as follows: carbapenems (13.8%), ceftazidime/avibactam (4 of 12, or 33.3%), and ceftolozane/tazobactam (7 of 15, or 46.7%). The most common infectious syndromes were pulmonary and central line-related infections, occurring in 38.5% and 23.1%, respectively. The 28-day mortality rate was 31.8%, 28-day clinical failure rate was 45.5%, and the 28-day microbiological failure rate was 31.8%. Conclusion Patients prescribed cefiderocol in this series had severe infections with high rates of mortality and few alternative antibiotic options. Susceptibility to cefiderocol was higher than for other antibiotics tested. Disclosures Barbara Trautner, MD, PhD, Genetech: Advisor/Consultant." @default.
• W4311732009 created "2022-12-28" @default.
• W4311732009 creator A5000701800 @default.
• W4311732009 creator A5031733730 @default.
• W4311732009 creator A5089886798 @default.
• W4311732009 date "2022-12-01" @default.
• W4311732009 modified "2023-09-30" @default.
• W4311732009 title "648. Cefiderocol as Rescue Therapy for <i>Pseudomonas aeruginosa</i> and Other Difficult-To-Treat Gram-Negative Infections" @default.
• W4311732009 doi "https://doi.org/10.1093/ofid/ofac492.700" @default.
• W4311732009 hasPublicationYear "2022" @default.
• W4311732009 type Work @default.
• W4311732009 citedByCount "0" @default.
• W4311732009 crossrefType "journal-article" @default.
• W4311732009 hasAuthorship W4311732009A5000701800 @default.
• W4311732009 hasAuthorship W4311732009A5031733730 @default.
• W4311732009 hasAuthorship W4311732009A5089886798 @default.
• W4311732009 hasBestOaLocation W43117320091 @default.
• W4311732009 hasConcept C177713679 @default.
• W4311732009 hasConcept C2426938 @default.
• W4311732009 hasConcept C2777637488 @default.
• W4311732009 hasConcept C501593827 @default.
• W4311732009 hasConcept C523546767 @default.
• W4311732009 hasConcept C54355233 @default.
• W4311732009 hasConcept C64778159 @default.
• W4311732009 hasConcept C71924100 @default.
• W4311732009 hasConcept C86803240 @default.
• W4311732009 hasConcept C89423630 @default.
• W4311732009 hasConcept C98274493 @default.
• W4311732009 hasConceptScore W4311732009C177713679 @default.
• W4311732009 hasConceptScore W4311732009C2426938 @default.
• W4311732009 hasConceptScore W4311732009C2777637488 @default.
• W4311732009 hasConceptScore W4311732009C501593827 @default.
• W4311732009 hasConceptScore W4311732009C523546767 @default.
• W4311732009 hasConceptScore W4311732009C54355233 @default.
• W4311732009 hasConceptScore W4311732009C64778159 @default.
• W4311732009 hasConceptScore W4311732009C71924100 @default.
• W4311732009 hasConceptScore W4311732009C86803240 @default.
• W4311732009 hasConceptScore W4311732009C89423630 @default.
• W4311732009 hasConceptScore W4311732009C98274493 @default.
• W4311732009 hasIssue "Supplement_2" @default.
• W4311732009 hasLocation W43117320091 @default.
• W4311732009 hasLocation W43117320092 @default.
• W4311732009 hasOpenAccess W4311732009 @default.
• W4311732009 hasPrimaryLocation W43117320091 @default.
• W4311732009 hasRelatedWork W2021850505 @default.
• W4311732009 hasRelatedWork W2030310773 @default.
• W4311732009 hasRelatedWork W2070790732 @default.
• W4311732009 hasRelatedWork W2169292189 @default.
• W4311732009 hasRelatedWork W2357979158 @default.
• W4311732009 hasRelatedWork W2537899196 @default.
• W4311732009 hasRelatedWork W2929616771 @default.
• W4311732009 hasRelatedWork W4293090417 @default.
• W4311732009 hasRelatedWork W4301403260 @default.
• W4311732009 hasRelatedWork W2482543893 @default.
• W4311732009 hasVolume "9" @default.
• W4311732009 isParatext "false" @default.
• W4311732009 isRetracted "false" @default.
• W4311732009 workType "article" @default.